A list of commonly used measurement tools for psoriasis management and clinical trials.
The DermSat-7 is a patient-reported outcome measure designed to assess patient satisfaction with psoriasis treatment. It consists of seven key questions evaluating treatment effectiveness, convenience, and overall satisfaction, providing valuable insights for both patients and healthcare providers.
A simple 10-question validated questionnaire that has been used for more than 40 different skin conditions in over 80 countries and is available in over 110 languages to measure disease severity and quality of life.
A simple proxy for PASI and DLQI using body surface area (BSA) and one or more of Skin Pain Visual Analog Score (Skin Pain VAS), Itch numeric rating scale (Itch NRS), and patient global assessment (patGA).
Quantifies the severity of psoriasis measured by redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
Physician’s assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic plaque psoriasis.
The Simplified Psoriasis Index (SPI) is a tool that has been developed to enable either healthcare professionals or patients with psoriasis to make regular assessments of disease severity and its impact on well-being. It also incorporates a summary of past behavior and treatment.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version and the Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
GET THE CDLQI
DOWNLOAD THE OFFICIAL APP (free) – Apple
DOWNLOAD THE OFFICIAL APP (free) – Google Play
A clinical tool used to assess the severity of nail psoriasis, focusing on specific features of nail involvement.
A clinical tool for evaluating the severity of psoriasis on the hands and feet. Based on erythema, scaling, and pustule presence, the PPPGA ranges from clear to severe.
A validated screening tool for psoriatic arthritis (PsA). It is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical assessment tool used to measure the severity of psoriasis specifically on the scalp, based on erythema, scaling, and thickness.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis.
A validated online measure designed to comprehensively evaluate disease activity in generalized pustular psoriasis, providing clinicians with a reliable tool to assess the severity and progression of the condition.
Includes validated tools that help clinicians accurately monitor disease severity, progression, and treatment response.
This confirms the reliability and accuracy in assessing disease severity and extent, providing essential tools for clinicians to effectively evaluate and manage generalized pustular psoriasis.
IPC does not endorse or accept any responsibility for the content of external websites.
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
